Overview

Study of Vitamin D3 Substitution to Patients With Primary Immunodeficiency

Status:
Completed
Trial end date:
2011-06-01
Target enrollment:
0
Participant gender:
All
Summary
Hypothesis: Cholecalciferol (vitamin D3) prevent respiratory tract infections in patients with primary immunodeficiency.
Phase:
Phase 1/Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Karolinska University Hospital
Treatments:
Cholecalciferol
Ergocalciferols
Vitamin D
Vitamins
Criteria
Inclusion Criteria:

- Age 18-75

- Increased number of respiratory tract infections

- At least 42 days of infections during 2008 or 2009

- S-25 OH vitamin D3 < 250 nM

- Not planning a pregnancy during the coming year

- Accepting the use of contraceptives during 1 year

Exclusion Criteria:

- Continuous antibiotic treatment

- Hypercalcemia

- Sarcoidosis

- Kidney disease

- Tuberculosis

- Pregnancy

- Kidney stone

- Heart medication (glycosides)